Cingulate Inc. (CING) witnessed a dramatic surge in its stock price following the granting of a European patent for its flagship ADHD treatment, CTx-1301. This patent extends across 30 European territories, including the United Kingdom, significantly strengthening Cingulate’s foothold in the global ADHD market.
This development marks a pivotal step for Cingulate, as the company prepares to file a New Drug Application (NDA) with the U.S. Food and Drug Administration. The innovative CTx-1301 treatment utilizes Cingulate’s Precision Timed Release technology, which delivers medication in three precisely timed releases throughout the day. This groundbreaking approach aims to provide patients with consistent medication effectiveness for the entire day, a significant improvement over existing therapies that often struggle to maintain efficacy throughout active periods.
The stock price of CING has surged by a remarkable 239% in the latest trading session, reaching $16.30 per share. This dramatic increase underscores the market’s confidence in Cingulate’s potential to revolutionize ADHD treatment with its innovative approach.
